CGT Global Blog
CGT Global News
Stay ahead in the dynamic world of Accelerating Cell and Gene Therapy with the CGT Global blog and news page. Explore insightful articles, industry updates, product updates, and expert analysis on all things CGT Global. Stay informed, inspired, and connected with CGT Global – your go-to source for cutting-edge insights in the ever-evolving realm of research, clinical projects and healthcare.
Meet CGT Global’s Scientific Team: Sophia Johnson Associate Director of Logistic Operations
For cell procurement and delivery operations to run smoothly, countless moving parts must align. From understanding the needs of a research project to scheduling donors, fulfilling orders, and ensuring precise delivery, every step must fit together seamlessly. So, who keeps everything ticking like a perfectly timed clock? Meet Sophia Johnson, Associate Director of Logistic Operations at CGT Global. Sophia has been with CGT Global for 6 years, bringing her background in psychology and a talent making the puzzle pieces fit applying her expert planning and organization skills. While at Sonoma State, Sophia…
Read More
Scaling Humanized Immune System Mouse Models: Optimize Your CD34+ Engraftment with High Quality Cells
Table of Contents CD34+ Humanized Immune System Mice MNC Cell Quality Assessment: Flow Cytometry Data from CGT Global Cell Viability Cell Purity Cell Count Sources of CD34+ Cells: Comparison Table for Bone Marrow and Cord Blood Bulk Isolated CD34+ for Humanized Mice About CGT Global and Additional Resources Frequently Asked Questions List of Abbreviations The Importance of Mice Humanized with Primary CD34+ Cells There is an urgent need for better therapies to treat individuals with life-limiting conditions. Yet, developing new medicines is…
Read More
Top PBMC Suppliers for 2026: Fresh, Cryopreserved, and GMP-Grade Options Compared
Introduction Peripheral Blood Mononuclear Cells (PBMCs) are foundational to immunology, oncology, and cell therapy research. Whether they are used for functional assays, vaccine development, or discovery-stage therapeutic studies, PBMC quality directly impacts data accuracy and reproducibility. In 2026, researchers expect more than just availability. They look for documented donor screening, consistent viability, and responsive support. This comparison reviews the top PBMC suppliers serving academic, biotech, and translational research programs, focusing on quality, logistics, and communication.(If you are deciding between collection methods, see…
Read More
Best Leukopak Suppliers for Cell Therapy in 2026: Pricing, Quality, and Turnaround Compared
Introduction When it comes to sourcing leukopaks for cell therapy or research, product quality is only half the story. Procurement delays, unanswered inquiries, and limited visibility can stall entire workflows. In 2026, speed and communication matter just as much as purity and yield. To help researchers, process developers, and procurement teams choose confidently, we reviewed leading leukopak suppliers on quality metrics, mobilization options, GMP compliance and increasingly – responsiveness. What to Look For in a Leukopak Supplier Beyond product specifications, the top-performing…
Read More
The Donors Powering Breakthroughs in Maternal and Infant Health
Every great discovery begins with a volunteer. At CGT Global, maternal blood donors are at the heart of pregnancy and infant health research. Their contributions help scientists understand how life begins, how the body adapts during pregnancy, and how to prevent complications that still threaten mothers and babies worldwide. When someone donates maternal blood, they are not just giving a sample. They are giving researchers a glimpse into one of the most complex and extraordinary biological processes on Earth. These donations are…
Read More
Scaling Cell & Gene Therapy Development: How CGT Global Supports Research, Clinical Trials, and Commercialization
By Joanna Wirkus, PhD From RUO to cGMP, CGT Global delivers quality, consistency, and regulatory readiness to help researchers advance therapies from discovery to patients. Executive Summary CGT Global accelerates cell and gene therapy development from discovery to commercialization. By providing rapid and reliable access to high-quality RUO and cGMP-certified materials and operating FDA- and CLIA-certified clinics co-located with cell specific labs, CGT Global ensures speed, consistency, and regulatory-ready CMC packages. This integration helps sponsors avoid delays, streamline clinical trials, and expand patient…
Read More
Meet CGT Global’s Scientific Team: Vanessa Murillo – Supervisor, Client Scientific Associate Team
October 08, 2025 Written by: Joanna Wirkus, PhD At CGT Global, advancing scientific discoveries worldwide by delivering high-quality biospecimens starts with providing exceptional service to our clients. Today, we’re highlighting how this happens by speaking with Vanessa Murillo, a core member and leader of CGT Global’s Client Scientific Associate team. Vanessa is a Client Scientific Associate Supervisor based in Reno, Nevada. Her and her team are dedicated to the success of CGT Global’s scientific partners and collaborators. Vanessa attended the University of…
Read More
5 Green Flags the FDA Looks for in CGT CMC and How to Get Them
Roughly 50 to 75 percent of FDA rejections in cell and gene therapy are not about safety or efficacy. They are due to CMC and manufacturing deficiencies. In short, most programs do not fail because the science does not work. They fail because the manufacturing story is not strong enough. (Sources: Jefferies analysis of FDA complete response letters, FiercePharma 2024; multiple CMC audit summaries 2020 to 2024) For CGT developers, Chemistry, Manufacturing, and Controls (CMC) is not a regulatory checkbox. It is…
Read More
Baby KJ Makes Headlines as the First Infant to Receive Personalized CRISPR Gene Editing Therapy
Written by Joanna Wirkus, PhD May 15, 2025, NPR ’s Science Friday spotlighted Baby KJ, the first infant to receive a personalized CRISPR-based gene editing treatment. The segment explored the groundbreaking therapy, the condition it aims to treat, and the collaborative effort behind this historic milestone. Here’s a summary of the key points from the report: What is Baby KJ’s Illness? What Are the Current Treatment Options? How Long Did FDA Approval Take? What Were Conversations Like With KJ’s Parents? How Was…
Read More
Alzheimer’s & Neurodegenerative Disease: A Global Challenge
Written by CGT Global Cell & Gene Therapy Is Shifting the Paradigm Recent CGT innovations are upending traditional models and opening new paths to treat or even reverse Alzheimer’s progression: 1. AAV-Based Gene Therapy (LX1001) 2. CRISPR-Engineered Microglia 3. Behavior-Reprogramming Gene Therapy (UC San Diego) 4. Stem Cells & MSC Therapies 5. iPSC TriCulture Models for Neuroinflammation 6. Targeting GlialMediated Inflammation Why This Matters for CGT & You The Road Ahead Final Word The convergence of CGT technologies—AAV vectors, CRISPR, iPSC, and…
Read More
Mesenchymal Stem Cell Derived Exosomes: Revolutionizing Future Medical Treatments
Why are scientists excited about Mesenchymal Stem Cell Exosomes? Mesenchymal stem cell (MSC) exosomes are on the brink of revolutionizing future treatments for chronic diseases and injuries. These microscopic biological messengers represent a vital mechanism of cellular communication, potentially offering a biomolecular reset for human physiological processes. The Unique Capabilities of Mesenchymal Stem Cells Mesenchymal stem cells possess unique adaptive properties and profound regenerative abilities. They can: Part of MSCs healing properties is their capacity to: Clinical Progress and Regulatory Validation for…
Read More
CGT Global Welcomes Dr. Jerome Ritz to Its Board of Advisors, Enriching Knowledge of Cellular Therapies and Hematology
By:CGT GlobalviaBusiness Wire August 14, 2025 at 09:00 AM EDT CGT Global, a biotechnology leader accelerating access to life-changing cell and gene therapies, today announced the appointment of Jerome Ritz, MD, to its Board of Advisors. Dr. Ritz brings a distinguished career in hematology, oncology, cell manufacturing, and the advancement of cell and gene therapies. This press release features multimedia. View the full release https://apnews.com/press-release/business-wire/cgt-global-welcomes-dr-jerome-ritz-to-its-board-of-advisors-enriching-knowledge-of-cellular-therapies-and-hematology-3250b55a87174e3b9376fb1b67567208# CGT Global Welcomes Dr. Jerome Ritz to Its Board of Advisors Dr. Ritz received his MD from…
Read More